Gonadotropin-releasing hormone (GnRH) analog depot preparations have now been in use for more than 15 years and
|
|
- Nigel Greer
- 5 years ago
- Views:
Transcription
1 REPRODUCTIVE OUTCOME IN PATIENTS TREATED AND NOT TREATED FOR IDIOPATHIC EARLY PUBERTY: LONG-TERM RESULTS OF A RANDOMIZED TRIAL IN ADULTS ALESSANDRA CASSIO, MD, MILVA O. BAL, MD, LUIGI F. ORSINI, MD, ANTONIO BALSAMO, MD, SILVIA SANSAVINI, MD, MONIA GENNARI, MD, ENRICO DE CRISTOFARO, MD, AND ALESSANDRO CICOGNANI, MD Objective To evaluate the adult reproductive outcome in girls with early puberty who participated in a previous random study. Study design A total of 22 subjects treated with triptorelin 3.75 mg every 4 weeks (group 1), 18 subjects not treated (group 2), and 22 age-matched normal volunteers (control group) underwent a physical examination, serum hormone level determination, and pelvic ultrasonography. Results The characteristics of menstrual cycles, serum hormone levels, and ultrasound results did not differ significantly among the 3 groups examined. The mean ovarian volume and the uterine volume tended to increase in the subjects of group 2, but the differences were not significant. The percentage of subjects who reported being sexually active at the time of the examination was greater in the 2 groups with previous early puberty than in the controls (76% of cases in group 1, 72% in group 2, and 59% in the control group). Conclusions Neither early puberty nor its treatment seems to significantly affect the normal adult function of the pituitarygonadal axis. (J Pediatr 2006;149:532-6) Gonadotropin-releasing hormone (GnRH) analog depot preparations have now been in use for more than 15 years and have became the treatment of choice for central precocious puberty (CPP). Many short-term follow up studies have documented the effectiveness, safety, and reversibility of the suppressive effects of this treatment. 1-3 For the many persons with CPP who have reached adulthood, long-term data is lacking on some outcomes, including gonadal and reproductive function, the appearance of polycystic ovary syndrome (POS), and body composition. 4-8 In particular, there have been no randomized controlled trials assessing long-term outcome in these persons to determine whether some aspects of the supposed side effects of treatment are instead consequences of the disease itself. 5,9,10 In a previous study, we examined 46 girls referred to us for early puberty and divided them randomly into 2 groups, 1 group treated with triptorelin and the other followed without treatment. 11 The aim of the present study was to evaluate the adult reproductive outcome in these 2 groups and in a normal control group. METHODS Patient Population A total of 46 girls referred to our center between 1991 and 1992 for early puberty (ie, onset of puberty at a mean of 7.7 years) were randomly divided into 2 groups: 1 group treated with triptorelin 3.75 mg every 4 weeks (group 1) and the other group followed without treatment (group 2). In group 1, treatment with triptorelin was provided for a mean of 25 months, and the subjects were followed up after treatment for a mean of 33 months until they reached adult height. The subjects in group 2 were followed up for a mean of 41 months. The final heights of the treated and untreated subjects were not significantly different. 11 In all cases, magnetic resonance imaging of the pituitary gland and pelvic ultrasound were performed to exclude organic pathologies. BMI CPP FSH Body mass index Central precocious puberty Follicle-stimulating hormone GnRH LH US Gonadotropin-releasing hormone Leutinizing hormone Ultrasound From the Department of Gynecology, Obstetrics and Pediatrics, University of Bologna, Italy. Submitted for publication Jan 25, 2006; last revision received Apr 5, 2006; accepted May 17, Reprint requests: Dr. Alessandra Cassio, Clinica Pediatrica, Policlinico S.Orsola-Malpighi, Via Massarenti 11, Bologna, Italy. cassio@med.unibo.it /$ - see front matter Copyright 2006 Mosby Inc. All rights reserved /j.jpeds
2 From June to December 2003, all girls previously recruited for the study were recalled, and 40 adult subjects (22 subjects of group 1, mean age [ standard deviation] years; 18 subjects of group 2, mean age, years) agreed to participate in the new examination. For comparative purposes, 22 age-matched normal volunteers (postgraduate students of a nursing school, mean age years) were examined as a control group. Written informed consent was obtained from all study participants. Protocol The following endocrine evaluations were obtained on days 17 to 23 of the menstrual cycle in subjects with sufficiently regular menses and at any point in the menstrual cycle in the other subjects: Gynecologic history, with evaluation of menstrual pattern and oral contraceptive use Physical examination, with evaluation of height, weight, and symptoms of hyperandrogenism (acne and/or hirsutism) Blood samples to determine basal levels of leutinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, progesterone, and delta-4-androstenedione Pelvic ultrasonography to assess uterine and ovarian volumes, uterine echos, and ovarian structure. We report hormonal and ultrasound data only for those subjects not taking oral contraception at the time of the study (17 subjects in group 1, 14 subjects in group 2, and 16 subjects in the control group). The characteristics of menstrual cycles were evaluated in a semistructured interview carried out by an expert clinician. The frequency of menstrual bleeding was classified as follows: regular (menses every 25 to 35 days), irregular (menses every 25 to 60 days), oligomenorrhea (menses at 35-day intervals), and polimenorrhea (menses at 22-day intervals). 5 Dysmenorrhea was defined as menstrual pain that necessitated analgesic drugs and/or did not permit normal daily activity. The body mass index (BMI) was calculated as weight in kg/height in m 2. Hirsutism was assessed using the Ferriman and Gallwey scale. 12 Hormonal determinations were performed using commercial kits as follows: FSH and LH were measured using an immunochemiluminometric assay (ICMA) commercial method (Bayer Healthcare, Diagnostic Division, Tarrytown, NY). Commercial ICMA kits were used also for progesterone and estradiol (Bayer Healthcare), and for delta-4-androstenedione (DPC, Los Angeles, CA). In accordance with Apter, 13 progesterone levels 2 ng/ml in the premenstrual phase of the cycle were assumed to signify an ovulatory cycle. The equipment used in the ultrasound (US) examinations included Sonoline Versa Plus (Siemens, Issaquah, WA) and SSD 1700 Aloka Dynaview II (Aloka Co., Ltd, Tokyo, Japan) instruments, with 5-MHz transabdominal and 6.5- MHz transvaginal probes. Transabdominal scans were performed through the conventional full-bladder technique, with the transvaginal route was used in sexually active subjects. All US examinations were carried out by the same sonographer, who was blinded to the subjects diagnoses. Uterine and ovarian volumes were calculated using the formula of the ellipsoid, as reported previously. 14 The mean ovarian volume was considered representative of both ovaries in each subject. The characteristics of the endometrium echos were evaluated to determine the uterine phase of the menstrual cycle. 14,15 The ovarian structure was defined as follows according to our experience 14,15 and literature data 16,17 : Normal, with functional signs of early/late follicular phase or luteal phase Multifollicular: Increased or normal ovarian volume, cystic areas of 4 to 10 mm diameter in an irregular distribution, normal stroma Micropolycystic: Normal ovarian volume, cystic areas of 2 to 8 mm diameter in a circumferential arrangement, hyperechoic stroma Polycystic: Increased ovarian volume, cystic areas of 2 to 8 mm diameter in a circumferential arrangement, large hyperechoic stroma. Statistical Analysis Results are expressed as mean standard deviation. Statistical analysis was performed with SPSS version (SPSS Inc, Chicago, IL). Differences between the groups were assessed by analysis of variance, and percentage differences were compared using the 2 test. All results nominally significant at P.05 were indicated. RESULTS Table I reports the menstrual patterns in the patients and controls examined. In group 1, the mean time at onset of menarche after discontinuation of triptorelin therapy was 16 9 months (range, 2 to 36 months). All subjects were examined more than 6 years after menarche. Table II reports clinical, US, and hormonal findings in the patients and controls examined. Four of the 22 subjects in group 1, 2 of the 18 subjects in group 2, and 4 of the 22 subjects in the control group had BMI values between 25 and 30 kg/m 2. No subjects showed marked obesity (BMI 30 kg/m 2 ). Ovarian volume was 10 ml in 19% (3/17) of the group 1 subjects, in 21% (3/14) of the group 2 subjects, and in 16% (2/16) of the controls. The characteristics of ovarian structures observed on US did not differ significantly among the 3 groups examined. A greater percentage of normal results was found in the group 1 subjects; a normal ovarian structure was observed in 14 of the 17 group 1 subjects (82%), 10 of the 14 group 2 subjects (71%), and 12 of 16 controls (75%). Direct signs (corpus luteum) or indirect signs (endometrial echo, progesterone levels) of ovulation were observed in 13 of the 14 normal subjects in group 1, in 9 of the 10 normal subjects in group 2, and in 10 of the 12 normal controls, with Reproductive Outcome In Patients Treated And Not Treated For Idiopathic Early Puberty: Long-Term Results Of A Randomized Trial In Adults 533
3 Table I. Menstrual function in subjects examined Age at menarche, (mean SD) years Years after menarche, (mean SD) years Girls reporting regular menses Girls reporting oligomenorrea Girls reporting dysmenorrea No. % No. % No. % Group /22 60% 1/22 4% 6/22 27% Group * /18 61% 1/18 5% 11/18 61% Controls /22 63% 1/22 4% 15/22 68% *P.005 versus controls. P.01 versus controls. Table II. Clinical, ultrasound, and hormonal findings in subjects examined BMI Uterine volume (ml) Mean ovarian volume (MOV) (ml) LH (mu/ml) FSH (mu/ml) Estradiol (pg/ml) Progesterone (ng/ml) Androstenedion (ng/dl) Group Group Controls normal functional signs of early or late follicular phase seen in the others. In all subjects with normal ovarian structure, the serum levels of gonadotropins, estradiol, and progesterone were within normal ranges for the phase of the menstrual cycle and were comparable in all groups. Table III reports clinical, US, and hormonal findings for those subjects in whom a multifollicular, micropolycystic, or polycystic ovarian structure was observed. In the 2 patients in whom a polycystic ovarian structure was observed at the diagnosis of CPP (Table III, cases 3 and 7), mean ovarian volume was 5.6 ml and 5.1 ml and the ovarian structure was microcystic. 5,18 The percentage of subjects who reported being sexually active at the time of the examination was greater in patients with previous early puberty than in controls, but this difference was not significant (76% of cases in group 1, 72% in group 2, and 59% in the control group). The number of subjects who used oral contraception was comparable in all 3 groups. Two girls of group 1 reported pregnancies (at age 17 and 17.5 years, respectively), both of which were terminated by elective abortion. DISCUSSION The few studies in the literature on the long-term outcome of patients with CPP involve adolescent girls or young women with both neurologic and idiopathic forms of CPP studied for an average of 1.5 to 3 years postmenarche. 4,5,8,19 The present long-term study takes into account a homogeneous sample of young women previously affected by idiopathic early puberty who were all examined more than 6 years after menarche as a reliable index of a complete maturation of the female reproductive function. 20 Moreover, the previous randomized trial allowed us to compare treated and untreated subjects with a control group to determine the influence of early puberty itself or treatment on future endocrine function. Although the size of the sample examined does not allow us to reach conclusive results, our data seem to demonstrate that neither early puberty nor its treatment significantly affects normal adult function of the pituitary-gonadal axis. We also must point out that the original sample of patients examined showed a slowly progressive variant of pubertal precocity in which height prognosis was not significantly improved by GnRH treatment. Our current results seem to confirm that the patients with early puberty exhibit a variant of normal puberty also in terms of menstrual pattern and reproductive outcome, and that GnRH treatment, at least for a few years, does not seem to affect this outcome adversely. Hormonal suppression achieved with GnRH analogues proved to be fully reversible in all cases, although the time of onset of menarche after the suspension of treatment varied widely. Because the type and duration of therapy were comparable in all cases examined, it is likely that this pattern simply indicates the natural variability of the phenomenon itself. To the best of our knowledge, the lower incidence of dysmenorrhea in treated subjects has not been reported in the literature, and the explanation appears questionable at present. Despite the restrictive criteria that we used to define dysmenorrhea, this symptom remains at least partially subjective, and its frequency may be overestimated due to the medical background of controls. Nonetheless, we must point out that the untreated patients reported the same frequency as controls and that a similar incidence of dysmenorrhea was found in a young population examined in a large study in postgraduate schools of Northern Italy. 21 Further studies with 534 Cassio et al The Journal of Pediatrics October 2006
4 Table III. Clinical, ultrasound, and hormonal findings in subjects with multifollicular, micropolycystic, and polycystic ovarian structure Cases Ovarian structure MOV (ml) BMI Clinical findings Menses LH/FSH Progesterone (ng/ml) Androstenedion (ng/dl) Group 1 Case 1 Multifollicular Acne Irregular Case 2 Micropolycystic Irregular Case 3 Polycystic Acne Regular Group 2 Case 4 Multifollicular Hirsutism Irregular Case 5 Micropolycystic Acne Irregular Case 6 Micropolycystic Acne Irregular Case 7 Polycystic Regular Control group Case 8 Micropolycystic Irregular Case 9 Micropolycystic Acne Regular Case 10 Polycystic Hirsutism Irregular Case 11 Polycystic Acne Regular more patients are needed to confirm this possible analgesic effect of GnRH analogue (GnRHa) treatment. Regarding the BMI changes in subjects with CPP, some authors have noted a progression toward marked obesity, especially in patients with hypothalamic hamartoma. 5,19 A recent study did not confirm this finding, however; on the contrary, it showed a favorable effect of GnRHa therapy on BMI decrease. 22 In agreement with those results, we found no cases of marked obesity in our study, and the incidence of borderline excess weight was comparable in patients and controls. The prevalence of enlarged ovaries in our patients was not significantly different from that in the controls and was comparable to that reported in previous studies. 8 The data in the literature concerning the occurrence of polycystic ovary (PCO) syndrome in CPP patients are controversial, but a very high incidence of PCO has been reported only in patients treated with a combination of GH and GnRHa, which is not a conventional therapy. 6,9,10 The characteristics of our protocol did not allow us to perform a diagnosis of PCO syndrome, defined according to Franks 23 as the association of hyperandrogenism with chronic anovulatory cycles in women without specific underlying disease of the adrenal or pituitary glands. Single symptoms of PCO syndrome were observed in both patients and controls, and our results confirm a previous report of a PCO prevalence of 23% in asymptomatic healthy women. 17 The pregnancies that occurred in our patients confirm the normal reproductive outcome in subjects with previous CPP; however, many report pregnancies occurring in young patients (as young as 13.8 and 15.9 years old) and often terminated with elective abortion as in our 2 cases. 4,5 These data, together with the apparent precocious sexual activity reported by our patients, warrant further investigatation to evaluate the psychosocial impact on sexual behavior of early sexual maturation. Finally, in this study we were unable to use a standardized quality-of-life questionnaire to evaluate the psychosocial impact of treatment (or no treatment) on the patients and their families. This information would simplify therapeutic decision making by the pediatrician, particularly in subjects with mild forms of precocious puberty. REFERENCES 1. Boepple PA, Mansfield MJ, Wierman ME, Rudlin CR, Bode HH, Crigler JF Jr, et al. Use of a potent, long-acting agonist of gonadotropinreleasing hormone in the treatment of precocious puberty. Endocr Rev 1986;7: Manasco PK, Pescovitz OH, Feuillan PP, Hench KD, Barnes KM, Jones J, et al. Resumption of puberty after long-term luteinizing hormonereleasing hormone agonist treatment of central precocious puberty. J Clin Endocrinol Metab 1988;67: Oostdijk W, Partsch CJ, Drop SLS, Sippell WG. Hormonal evaluation during and after long-term treatment with a slow-release GnRh agonist of children with central precocious puberty; effect on final height. In: Plant TM, Lee PA, eds. The neurobiology of puberty. Bristol, UK: Society for Endocrinology; 1995: Jay N, Mansfield MJ, Blizzard RM, Crowley WF, Schoenfeld DJ, Rhubin L, et al. Ovulation and menstrual function of adolescent girls with central precocious puberty after therapy with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab 1992;75: Feuillan PP, Jones JV, Barnes K, Oerter-Klein K, Cutle GB, Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long-term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab 1999;84: Bridges NA, Cooke A, Healy MJR, Hindmarsh PC, Brook CGD, Ovaries in sexual precocity. Clin Endocrinol (Oxf) 1995;42: Lazar L, Kauli R, Bruchis C, Nordenberg J, Galatzer A, Pertzelan A. Early polycystic ovary-like syndrome in girls with central precocious puberty and exaggerated adrenal response. Eur J Endocrinol 1995;133: Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 1999;84: Tatò L, Savage MO, Antoniazzi F, Buzi F, Di Maio S, Oostdijk W, et al. Optimal therapy of pubertal disorders in precocious/early puberty. J Ped Endocrinol Metab 2001;14: Reproductive Outcome In Patients Treated And Not Treated For Idiopathic Early Puberty: Long-Term Results Of A Randomized Trial In Adults 535
5 10. Tonini G, Lazzerini M, Side effects of GnRh analogue treatment in childhood. J Ped Endocrinol Metab 2000;13: Cassio A, Cacciari E, Balsamo A, Bal MO, Tassinari D. Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged years. Arch Dis Child 1999;81: Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21: Apter D. Serum steroids and pituitary hormones in female puberty: a partly longitudinal study. Clin Endocrinol 1980;12: Orsini LF, Salardi S, Pilu G, Bovicelli L, Cacciari E. Pelvic organs in premenarcheal girls: real-time ultrasonography. Radiology 1984;153: Salardi S, Orsini LF, Cacciari E, Partesotti S, Brondelli L, Cicognani A, et al. Pelvic ultrasonography in girls with precocious puberty, congenital adrenal hyperplasia, obesity or hirsutism. J Pediatr 1988;112: Adams J, Polson DW, Frank SS. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. BMJ;293: Polson DW, Wadsworth J, Franks S. Polycystic ovaries: a common finding in normal women. Lancet 1988;1: Cacciari E, Cassio A, Balsamo A, Colli C, Cicognani A, Pirazzoli P, et al. Long-term follow-up and final height in girls with central precocious puberty. Arch Pediatr Adolesc Med 1994;148: Feuillan PP, Jones JV, Barnes K, Oerter-Klein K, Cutler GB Jr. Follow-up of children and young adults after GnRH-agonist therapy for central precocious puberty. J Endocrinol Invest 2001;24: Porcu E, Venturoli S, Fabbri R, Orsini LF, Sganga E, Brondelli L, et al. Uterine development and endocrine relationships after menarche. Am J Obstet Gynecol 1989;161: Rigon F, Bianchin L, Persinotto E, Antoniazzi F, Bernasconi S, Bona G, et al. Frequenza della sindrome premestruale e della dismenorrea nelle giovani italiane [abstract]. SIEDP News 2003; Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, Segni M, Rosano M, et al. Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precpcious puberty. Eur J Endocrinol 2004;150: Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333: Cassio et al The Journal of Pediatrics October 2006
Imaging in Pediatric and Adolescent Gynecology
Background and Tools Sultan C (ed): Pediatric and Adolescent Gynecology. Evidence-Based Clinical Practice. Endocr Dev. Basel, Karger, 2004, vol 7, pp 9 22 Imaging in Pediatric and Adolescent Gynecology
More informationLong-Term Experience with GnRH Agonist Treatment of Central Precocious Puberty
Clin Pediatr Endocrinol 1993; (Supp13):49-56 Copyright (C)1993 by The Japanese Society for Pediatric Endocrinology Long-Term Experience with GnRH Agonist Treatment of Central Precocious Puberty Paul A.
More informationThe Effects of Gonadotropin Releasing Hormone Analogue Therapy on Girls with Gonadotropin-dependent Precocious Puberty
ORIGINAL ARTICLE The Effects of Gonadotropin Releasing Hormone Analogue Therapy on Girls with Gonadotropin-dependent Precocious Puberty Yi-Ching Tung, Jing-Sheng Lee, Wen-Yu Tsai, Pei-Hung Hsiao Background/Purpose:
More information2.0 Synopsis. Lupron Depot M Clinical Study Report R&D/09/093. (For National Authority Use Only) to Part of Dossier: Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: Name of Study Drug: Volume: Abbott-43818 (ABT-818) leuprolide acetate for depot suspension (Lupron Depot ) Name of
More informationPrevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty
Prevalence of polycystic ovary syndrome in young women who had idiopathic central precocious puberty Roberto Franceschi, M.D., a Rossella Gaudino, M.D., a Alma Marcolongo, M.D., b Maria Chiara Gallo, M.D.,
More informationAccepted 13 July, 2011
Journal of Medicine and Medical Science Vol. 2(7) pp. 955-960, July 2011 Available online@ http://www.interesjournals.org/jmms Copyright 2011 International Research Journals Full Length Research Paper
More informationReproductive Health and Pituitary Disease
Reproductive Health and Pituitary Disease Janet F. McLaren, MD Assistant Professor Division of Reproductive Endocrinology and Infertility Department of Obstetrics and Gynecology jmclaren@uabmc.edu Objectives
More informationDr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO
Dr Stella Milsom Endocrinologist Fertility Associates Auckland 12:30-12:40 When Puberty is PCO Puberty or Polycystic Ovary Syndrome? Stella Milsom Endocrinologist Auckland DHB, University of Auckland,
More informationPolycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018
Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018 Learning Objectives At the conclusion of this lecture, learners should: 1) Know the various diagnostic
More informationZohreh Karamizadeh, MD; Anis Amirhakimi*, MD; Gholamhossein Amirhakimi, MD
Original Article Iran J Pediatr Jun 2014; Vol 24 (No 3), Pp: 293-299 Effect of Pubertal Suppression on Linear Growth and Body Mass Index; a Two-Year Follow-Up in Girls with Genetic Short Stature and Rapidly
More informationPolycystic Ovarian Syndrome (PCOS) LOGO
Polycystic Ovarian Syndrome (PCOS) Ma qianhong Ob/Gyn Department LOGO Contents Epidemiology and Definition Pathophysiology, Endocrinological Features Diagnostic Criteria Treatment Prognosis Introduction
More informationOvarian and Uterine Findings in Pelvic Sonography
Article Ovarian and Uterine Findings in Pelvic Sonography Comparison Between Prepubertal Girls, Girls With Isolated Thelarche, and Girls With Central Precocious Puberty Liliane Diefenthaeler Herter, PhD,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,900 116,000 120M Open access books available International authors and editors Downloads Our
More informationLaura Stewart, MD, FRCPC Clinical Associate Professor Division of Pediatric Endocrinology University of British Columbia
Precocious Puberty Laura Stewart, MD, FRCPC Clinical Associate Professor Division of Pediatric Endocrinology University of British Columbia Faculty Disclosure Faculty: Laura Stewart No relationships with
More informationOverview of Reproductive Endocrinology
Overview of Reproductive Endocrinology I have no conflicts of interest to report. Maria Yialamas, MD Female Hypothalamic--Gonadal Axis 15 4 Hormone Secretion in the Normal Menstrual Cycle LH FSH E2, Progesterone,
More information12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman
Polycystic Ovarian Syndrome (PCOS) for the Family Physician Barbara S. Apgar MD, MS Professor or Family Medicine University of Michigan Ann Arbor, Michigan Important references for PCOS Endocrine Society
More informationHormonal Control of Human Reproduction
Hormonal Control of Human Reproduction Bởi: OpenStaxCollege The human male and female reproductive cycles are controlled by the interaction of hormones from the hypothalamus and anterior pituitary with
More informationPelvic sonography and uterine artery color Doppler analysis in
Ultrasound Obstet Gynecol 2002; 19: 386 391 Pelvic sonography and uterine artery color Doppler analysis in Blackwell Science Ltd the diagnosis of female precocious puberty C. BATTAGLIA*, G. REGNANI, F.
More informationROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)
ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU) In 1935, Stein and Leventhal described 7 women with bilateral enlarged PCO, amenorrhea or irregular menses, infertility and masculinizing
More informationGonadotrophin treatment in patients with Polycystic Ovary Syndrome
Int. J. Adv. Res. Biol. Sci. (218). 5(4): 95-99 International Journal of Advanced Research in Biological Sciences ISSN: 2348-869 www.ijarbs.com DOI: 1.22192/ijarbs Coden: IJARQG(USA) Volume 5, Issue 4-218
More informationKJLM. Gonadotropin-releasing Hormone Stimulation Test for Precocious Puberty INTRODUCTION. Original Article Clinical Chemistry
Korean J Lab Med 2011;31:244-249 Original Article Clinical Chemistry Gonadotropin-releasing Hormone Stimulation Test for Precocious Puberty Han Kyul Kim, M.D. 1, Seung Jung Kee, M.D. 2, Ji Yeon Seo, M.D.
More informationEtiologies of Precocious Puberty: 15-Year Experience in a Tertiary Hospital in Southern Thailand
Freund Publishing House Ltd., London Journal of Pediatric Endocrinology & Metabolism, 23, 1263-1271 (2010) Etiologies of Precocious Puberty: 15-Year Experience in a Tertiary Hospital in Southern Thailand
More informationX/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Copyright 2006 by The Endocrine Society doi: /jc.
0021-972X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Printed in U.S.A. Copyright 2006 by The Endocrine Society doi: 10.1210/jc.2005-1457 EXTENSIVE CLINICAL EXPERIENCE Relative
More informationPrecocious Puberty. Disclosures. No financial disclosures 2/28/2019
Precocious Puberty Bracha Goldsweig, MD Pediatric Endocrinologist Children s Hospital and Medical Center, Omaha, NE University of Nebraska Medical Center Disclosures No financial disclosures 1 Objectives
More informationClinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE
Clinical Guideline ADRENARCHE MANAGEMENT OF CHILDREN PRESENTING WITH SIGNS OF EARLY ONSET PUBIC HAIR/BODY ODOUR/ACNE Includes guidance for the distinction between adrenarche, precocious puberty and other
More informationClinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes
POLYCYSTIC OVARY SYNDROME Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes Ettore Guastella, M.D., a Rosa Alba Longo, M.D., b and Enrico Carmina, M.D. b a Department
More informationPedsCases Podcast Scripts
PedsCases Podcast Scripts This is a text version of a podcast from Pedscases.com on Puberty and Pubertal Disorders Part 2: Precocious Puberty. These podcasts are designed to give medical students an overview
More informationReproductive Hormones
Reproductive Hormones Male gonads: testes produce male sex cells! sperm Female gonads: ovaries produce female sex cells! ovum The union of male and female sex cells during fertilization produces a zygote
More informationlactotrophs 120 min- FSH 60 min- LH Hypothalamus GnRH pituitary Estradiol +/- Progesterone _ FSH L H Ovary Uterus Ovulation Antral follicle >2mm
lactotrophs Hypothalamus GnRH 120 min- 60 min- LH Progesterone _ pituitary L H + Ovary + Estradiol +/- Uterus Antral follicle >2mm Ovulation Preovulatory follicles atresia Follicular phase Luteal phase
More informationStandards for ovarian volume in childhood and puberty*
FERTILITY AND STERILITY Copyright 1993 The American Fertility Society Printed on acid-free paper in U. S. A. Standards for ovarian volume in childhood and puberty* Nicola A. Bridges, B.M.t Alex Cooke,
More informationusually, but not always, enlarged.' These are features that can be identified using high resolution ultrasonography of the ovaries.
BRITISH MEDICAL JOURNAL VOLUME 293 9 AUGUST 1986 355 PAPERS AND SHORT REPORTS Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism J ADAMS, D W POLSON, S FRANKS Abstract
More informationFollow-up Study of Adolescent Girls With a History of Premature Pubarche
JOURNAL OF ADOLESCENT HEALTH 1996;18:301-305 ADOLESCENT HEALTH BRIEF/FELLOWSHIP FORUM Follow-up Study of Adolescent Girls With a History of Premature Pubarche DAPHNE MILLER, M.D., S. JEAN EMANS, M.D.,
More informationCASE 41. What is the pathophysiologic cause of her amenorrhea? Which cells in the ovary secrete estrogen?
CASE 41 A 19-year-old woman presents to her gynecologist with complaints of not having had a period for 6 months. She reports having normal periods since menarche at age 12. She denies sexual activity,
More informationFemale Reproductive System. Lesson 10
Female Reproductive System Lesson 10 Learning Goals 1. What are the five hormones involved in the female reproductive system? 2. Understand the four phases of the menstrual cycle. Human Reproductive System
More informationJessicah S. Collins, Jennifer P. Beller, Christine Burt Solorzano, James T. Patrie, R. Jeffrey Chang, John C. Marshall, Christopher R.
Supplemental Materials for manuscript entitled Blunted Day-Night Changes in Luteinizing Hormone Pulse Frequency in Girls with Obesity: the Potential Role of Hyperandrogenemia Jessicah S. Collins, Jennifer
More informationEuropean Journal of Endocrinology (2010) ISSN
European Journal of Endocrinology (2010) 163 55 62 ISSN 0804-4643 CLINICAL STUDY GNRH analog therapy in girls with early puberty is associated with the achievement of predicted final height but also with
More informationReproductive physiology
Reproductive physiology Sex hormones: Androgens Estrogens Gestagens Learning objectives 86 (also 90) Sex Genetic sex Gonadal sex Phenotypic sex XY - XX chromosomes testes - ovaries external features Tha
More informationclinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome
& clinical outcome and hormone profiles before and after laparoscopic electroincision of the ovaries in women with polycystic ovary syndrome Zulfo Godinjak¹*, Ranka Javorić² 1 Gynecology and Obstetrics
More informationInvestigation: The Human Menstrual Cycle Research Question: How do hormones control the menstrual cycle?
Investigation: The Human Menstrual Cycle Research Question: How do hormones control the menstrual cycle? Introduction: The menstrual cycle (changes within the uterus) is an approximately 28-day cycle that
More information16 YEAR-OLD OBESE FEMALE WITH OLIGOMENORRHEA
16 YEAR-OLD OBESE FEMALE WITH OLIGOMENORRHEA Katie O Sullivan, MD Adult/Pediatric Endocrinology Fellow University of Chicago ENDORAMA Thursday, September 4th, 2014 Disclosures No financial interests. Will
More informationThe prevalence of polycystic ovaries in healthy women
Acta Obstet Gynecol Scand 1999; 78: 137 141 Copyright C Acta Obstet Gynecol Scand 1999 Printed in Denmark all rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 ORIGINAL ARTICLE
More informationV. CALCATERRA*, P. SAMPAOLO, C. KLERSY, D. LARIZZA*, A. ALFEI, V. BRIZZI*, F. BENEVENTI and M. CISTERNINO*
Ultrasound Obstet Gynecol 2009; 33: 85 91 Published online 11 December 2008 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/uog.6271 Utility of breast ultrasonography in the diagnostic
More information1. During the follicular phase of the ovarian cycle, the hypothalamus releases GnRH.
1. During the follicular phase of the ovarian cycle, the hypothalamus releases GnRH. 2. This causes the anterior pituitary to secrete small quantities of FSH and LH. 3. At this time, the follicles in the
More informationAbnormal Uterine Bleeding Case Studies
Case Study 1 Abnormal Uterine Bleeding Case Studies Abigail, a 24 year old female, presents to your office complaining that her menstrual cycles have become a problem. They are now lasting 6 7 days instead
More informationCase. 24 year old female presented to your office complaining of excess hair growth on her face and abdomen. Questions?
Hirsutism Case 24 year old female presented to your office complaining of excess hair growth on her face and abdomen Questions? Started around puberty with gradual progression Irregular menstrual cycle
More informationUltrasound of Uterus and Ovary
1 of 16 5/3/2005 8:34 PM Contents: Ultrasound of Uterus and Ovary Introduction Section 1: The Normal Ovary by Ultrasound Section 2: Ultrasound of Normal Ovarian Follicular Cycles Section 3: Ultrasound
More informationA single sample GnRHa stimulation test in the diagnosis of precocious puberty
Yazdani et al. International Journal of Pediatric Endocrinology 212, 212:23 RESEARCH Open Access A single sample GnRHa stimulation test in the diagnosis of precocious puberty Parvin Yazdani 1*, Yuezhen
More information2-Hypertrichosis:- Hypertrichosis is the
Hirsutism And Virilization Hirsutism:- Is the development of androgen-dependent dependent terminal body hair in a woman in places in which terminal hair is normally not found, terminal body hairs are the
More informationNeil Goodman, MD, FACE
Initial Workup of Infertile Couple: Female Neil Goodman, MD, FACE Professor of Medicine Voluntary Faculty University of Miami Miller School of Medicine Scope of Infertility in the United States Affects
More informationPolycystic Ovary Syndrome
Polycystic Ovary Syndrome Definition: the diagnostic criteria Evidence of hyperandrogenism, biochemical &/or clinical (hirsutism, acne & male pattern baldness). Ovulatory dysfunction; amenorrhoea; oligomenorrhoea
More informationThe effect of gonadotropin-releasing hormone agonist on thyroid-stimulating hormone and prolactin secretion in adult premenopausal women
FERTILITY AND STERILITY Vol. 64, No.4, October 1995 Copyright 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. The effect of gonadotropin-releasing hormone agonist
More informationThe reproductive lifespan
The reproductive lifespan Reproductive potential Ovarian cycles Pregnancy Lactation Male Female Puberty Menopause Age Menstruation is an external indicator of ovarian events controlled by the hypothalamicpituitary
More informationCase Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation
Polycystic Ovarian Syndrome: Treatment Goals and Options Marc Cornier, MD Division of Endocrinology, Metabolism and Diabetes Colorado Center for Health and Wellness University of Colorado School of Medicine
More informationThe Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (1), Page 63-69
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (1), Page 63-69 Effect of Metformin Only versus Effect of Metformin and Corticosteroids after Laparoscopic Ovarian Drilling on Ovulation
More informationRole of surgical resection in the treatment of hypothalamic hamartomas causing precocious puberty Report of six cases
Role of surgical resection in the treatment of hypothalamic hamartomas causing precocious puberty Report of six cases Laura Stewart, M.D., F.R.C.P.(C), Paul Steinbok, M.B.B.S., F.R.C.S.(C), and Jorge Daaboul,
More informationAchieving Pregnancy: Obesity and Infertility. Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center
Achieving Pregnancy: Obesity and Infertility Jordan Vaughan, MSN, APN, WHNP-BC Women s Health Nurse Practitioner Nashville Fertility Center Disclosures Speakers Bureau EMD Serono Board of Directors Nurse
More informationReproductive FSH. Analyte Information
Reproductive FSH Analyte Information 1 Follicle-stimulating hormone Introduction Follicle-stimulating hormone (FSH, also known as follitropin) is a glycoprotein hormone secreted by the anterior pituitary
More informationUterus & Ovary 2015; 2: e904. doi: /uo.904; 2015 by Ahmed M Maged, et al.
RESEARCH ARTICLE Phytoestrogens as an alternative to estradiol in reversing the antiestrogenic effect of clomid on endometrium in ovulation induction in cases of polycystic ovarian syndrome (PCOS) Ahmed
More informationGynecology-endocrinology
Gynecology-endocrinology FERTILITY AND STERILITY Copyright c 1994 The American Fertility Society Vol. 61, No.5, May 1994 Printed on acid-free paper in U. S. A. Treatment of moderate and severe hirsutism
More informationNitasha Garg 1 Harkiran Kaur Khaira. About the Author
https://doi.org/10.1007/s13224-017-1082-4 ORIGINAL ARTICLE A Comparative Study on Quantitative Assessment of Blood Flow and Vascularization in Polycystic Ovary Syndrome Patients and Normal Women Using
More informationPrescribing Guidelines Prescribing arrangement for the management of patients transferring from Secondary Care to Primary Care
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationTreatment of hirsutism with a gonadotropin-releasing hormone agonist and estrogen replacement therapy*
Gynecology-endocrinology FERTILITY AND STERILITY Copyright 1994 The American Fertility Society Printed on acid-free paper in U S. A. Treatment of hirsutism with a gonadotropin-releasing hormone agonist
More informationPolycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology
Polycystic Ovarian Syndrome Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology Outline Definition Symptoms Causal factors Diagnosis Complications Treatment Why are we talking about
More informationFrequency of menses. Duration of menses 3 days to 7 days. Flow/amount of menses Average blood loss with menstruation is 60-80cc.
Frequency of menses 24 days (0.5%) to 35 days (0.9%) Age 25, 40% are between 25 and 28 days Age 25-35, 60% are between 25 and 28 days Teens and women over 40 s cycles may be longer apart Duration of menses
More informationPrecocious Puberty (Complete, Partial)
The Prepubertal Girl Sultan C (ed): Pediatric and Adolescent Gynecology. Evidence-Based Clinical Practice. Endocr Dev. Basel, Karger, 2004, vol 7, pp 57 65 Precocious Puberty (Complete, Partial) R. Stanhope,
More informationPOTION OR POISON? MEDICAL TREATMENT ALTERNATIVES TO THE PILL. Lester Ruppersberger, D.O., FACOOG,CNFPI NFP only Gynecologist
POTION OR POISON? MEDICAL TREATMENT ALTERNATIVES TO THE PILL Lester Ruppersberger, D.O., FACOOG,CNFPI NFP only Gynecologist THE PILL Released to US market in 1960 10-15 x dose of hormones in HRT Over 10-14
More informationTreatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty
Original article https://doi.org/10.6065/apem.2017.22.4.259 Ann Pediatr ocrinol Metab 2017;22:259-265 Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious
More informationCynthia Morris DO, FACOOG, FACOS Medical Director, Women s Wellness Center Fayette County Memorial Hospital
Cynthia Morris DO, FACOOG, FACOS Medical Director, Women s Wellness Center Fayette County Memorial Hospital Touchdown to CME Eighth District Academy of Osteopathic Medicine & Surgery October 8. 2017 Goals
More informationStage 4 - Ovarian Cancer Symptoms
WELCOME Stage 4 - Ovarian Cancer Symptoms University of Baghdad College of Nursing Department of Basic Medical Sciences Overview of Anatomy and Physioloy II Second Year Students Asaad Ismail Ahmad,
More informationJMSCR Vol 05 Issue 05 Page May 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.14 Hyperinsulinemia in Polycystic Ovary Syndrome
More informationClinical Study Evaluating the Efficacy of Treatment with a GnRH Analogue in Patients with Central Precocious Puberty
International Endocrinology Volume 2015, Article ID 247386, 7 pages http://dx.doi.org/10.1155/2015/247386 Clinical Study Evaluating the Efficacy of Treatment with a GnRH Analogue in Patients with Central
More informationPolycystic Ovary Syndrome Therapy Dr. Pilar Vigil MD, PhD, FACOG
Polycystic Ovary Syndrome Therapy Dr. Pilar Vigil MD, PhD, FACOG What is an ovulatory dysfunction? Mrs. Susana Godoy, Nurse-Midwife San José, Costa Rica Abril 2018 PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE
More informationCY Tse, AMK Chow, SCS Chan. Introduction
Effects of an extended-interval dosing regimen of triptorelin depot on the hormonal profile of patients with endometriosis: prospective observational study CY Tse, AMK Chow, SCS Chan Objective. To evaluate
More informationDiagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome
Endocrine Journal 2007, 54 (2), 233 238 Diagnostic Performance of Serum Total Testosterone for Japanese Patients with Polycystic Ovary Syndrome TAKESHI IWASA, TOSHIYA MATSUZAKI, MASAHIRO MINAKUCHI, NAOKO
More informationEndocrinologic features of oligomenorrheic adolescent girls*
FERTILITY AND STERILITY Copyright 1986 The American Fertility Society Printed in U.SA. Endocrinologic features of oligomenorrheic adolescent girls* Rita Siegberg, M.D. t Carl Gustaf Nilsson, M.D. Ulf-Hakan
More informationProf.Dr. Nabil Lymon Head of Internal Medicine Department
By Prof.Dr. Nabil Lymon Head of Internal Medicine Department Definitions: Hirsutism: Is the presence of terminal hair in androgendependent sites where hair does not normally grow in women. This hair growth
More informationPCOS and Obesity DUB is better treated by OCPs
PCOS and Obesity DUB is better treated by OCPs Dr. Ritu Joshi Senior consultant Fortis escorts Hospital, Jaipur Chairperson Family welfare com. FOGSI (20092012) Vice President FOGSI 2014 Introduction One
More informationEndocrine control of female reproductive function
Medicine School of Women s & Children s Health Discipline of Obstetrics & Gynaecology Endocrine control of female reproductive function Kirsty Walters, PhD Fertility Research Centre, School of Women s
More informationCan Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome?
www.ijpm.in www.ijpm.ir Can Sex hormone Binding Globulin Considered as a Predictor of Response to Pharmacological Treatment in Women with Polycystic Ovary Syndrome? Ferdous Mehrabian, Maryam Afghahi Department
More informationUltrasound Assessment of Breast Development: Distinction Between Premature Thelarche and Precocious Puberty
Pediatric Imaging Original Research Youn et al. Ultrasound Assessment of Breast Development Pediatric Imaging Original Research Inyoung Youn 1 Sung Hee Park 2 In Seok Lim 3 Soo Jin Kim 2 Youn I, Park SH,
More informationConcentrations of Luteinizing Hormone and Ovulatory Responses in Dairy Cows Before Timed Artificial Insemination
Concentrations of Luteinizing Hormone and Ovulatory Responses in Dairy Cows Before Timed Artificial Insemination S. L. Pulley, D. H. Keisler, S. L. Hill, and J. S. Stevenson Summary The objective of this
More informationClinical Problems in the Diagnosis and Treatment of PCOS During Adolescence
Clinical Problems in the Diagnosis and Treatment of PCOS During Adolescence R a c h a n a S h a h, M D M S T A s s i s t a n t P r o f e s s o r o f P e d i a t r i c s D i v i s i o n o f E n d o c r
More informationClinical Study and Outcome of Polycystic Ovarian Syndrome
NJOG 2011 May-June; 6 (1): 22-27 Clinical Study and Outcome of Polycystic Ovarian Syndrome Gayatri Linganagouda Patil 1, Geeta Hosanemati 1, L.S.Patil 2, Vijayanath.V 3, Venkatesh M Patil 4, Rajeshwari.
More informationApproach to ovulation induction and superovulation in women with a history of infertility. Anatte E. Karmon, MD
Approach to ovulation induction and superovulation in women with a history of infertility Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the
More information9.4 Regulating the Reproductive System
9.4 Regulating the Reproductive System The Reproductive System to unite a single reproductive cell from a female with a single reproductive cell from a male Both male and female reproductive systems include
More informationKey words: polycystic ovary syndrome, hypothalmic-pituitary-ovarian axes
Clin Pediatr Endocrinol 1999; 8(2), 77-84 Copyright 1999 by The Japanese Society for Pediatric Endocrinology Clinical, Hormonal, and Radiological Studies at Baseline, During and After Long Term GnRH Analog
More informationEstimation and occurrence of polycystic ovary among Sudanese woman's 2018
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 17, Issue 5 Ver. 15 (May. 2018), PP 64-72 www.iosrjournals.org Estimation and occurrence of polycystic
More informationEndocrinology of the Female Reproductive Axis
Endocrinology of the Female Reproductive Axis girlontheriver.com Geralyn Lambert-Messerlian, PhD, FACB Professor Women and Infants Hospital Alpert Medical School at Brown University Women & Infants BROWN
More informationDr Mary Birdsall. Fertility Associates Auckland
Dr Mary Birdsall Fertility Associates Auckland Period Problems Mary Birdsall Medical Director Fertility Associates Auckland Period Problems Basic Physiology No Periods Irregular Periods Heavy Periods
More informationDepartment of Obstetrics and Gynecology, University of Modena, Modena, Italy
FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Metformin administration modulates
More informationManagement of Adolescent Hyperandrogenism
Management of Adolescent Hyperandrogenism 4 Charles Sultan, Laura Gaspari, and Françoise Paris 4.1 Introduction Androgen excess during puberty produces a variety of clinical signs and symptoms that must
More informationChapter 14 Reproduction Review Assignment
Date: Mark: _/45 Chapter 14 Reproduction Review Assignment Multiple Choice Identify the choice that best completes the statement or answers the question. 1. Use the diagram above to answer the next question.
More informationAdolescent Gynecology: Evaluation and Management of Adnexal Mass, PCOS, and Endometriosis. Shanna M. Combs, MD
Adolescent Gynecology: Evaluation and Management of Adnexal Mass, PCOS, and Endometriosis Shanna M. Combs, MD Adolescent Visit and Exam Adolescent Reproductive Health Visit Initial visit should take place
More informationPolycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks
Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks Kate D. Schoyer, M.D. May 6, 2016 Objectives To review how to make the diagnosis of Polycystic Ovarian Syndrome (PCOS)
More informationReproductive hormones and epilepsy
3 rd Congress of the European Academy of Neurology Amsterdam, The Netherlands, June 24 27, 2017 Teaching Course 7 Treatment of women with epilepsy - Level 1-2 Reproductive hormones and epilepsy Gerhard
More informationPCOS IN ADOLESCENTS: EARLY DETECTION AND INTERVENTION
PCOS IN ADOLESCENTS: EARLY DETECTION AND INTERVENTION R A C H A N A S H A H, M D M S T R A S S I S TA N T P R O F E S S O R O F P E D I AT R I C S D I V I S I O N O F E N D O C R I N O L O G Y A N D D
More informationKENJI OHYAMA, MASANORI OHTA, YosHIKo NAKAGOMI, YOSHIE SHIMURA, T0M0AKI SANG, KAZUMASA SATO, SHINPEI NAKAZAWA, AND HIROMICHI ISHIKAWA*
Endocrine Journal 1997, 44 (4), 459-465 Restoration of Seminiferous Tubular Function after Discontinuation of Long-Term Gonadotropin-Releasing Hormone Agonist Administration in Premature Male Rats KENJI
More informationSCREENING OF POLYCYSTIC OVARIAN SYNDROME AMONG ADOLESCENT GIRLS AT CAIRO UNIVERSITY
SCREENING OF POLYCYSTIC OVARIAN SYNDROME AMONG ADOLESCENT GIRLS AT CAIRO UNIVERSITY Sahar Mansour Ibrahim, Yossria Ahmed Elsayed, Reda Esmail Reyad 4 and Hanan Fahmy Azzam 1* 2 3 1 Assistant Lecturer,
More informationChapter 27 The Reproductive System. MDufilho
Chapter 27 The Reproductive System 1 Figure 27.19 Events of oogenesis. Before birth Meiotic events 2n Oogonium (stem cell) Mitosis Follicle development in ovary Follicle cells Oocyte 2n Primary oocyte
More informationARTICLE. Primary Amenorrhea as a Manifestation of Polycystic Ovarian Syndrome in Adolescents
ARTICLE Primary Amenorrhea as a Manifestation of Polycystic Ovarian Syndrome in Adolescents A Unique Subgroup? Marianna Rachmiel, MD; Sari Kives, MD; Eshetu Atenafu, MSc; Jill Hamilton, MD, MSc Objective:
More information